On the public citation graph
https://doi.org/10.2139/ssrn.5366120
0 signed · 28 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s00262-012-1388-0openalex-extracted
Chemoimmunotherapy: reengineering tumor immunity
inferredcites →https://doi.org/10.1007/s11523-023-00981-7openalex-extracted
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.annonc.2022.10.006openalex-extracted
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
inferredcites →https://doi.org/10.1016/j.cell.2020.08.053openalex-extracted
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
inferredcites →https://doi.org/10.1016/j.jtcvs.2023.12.030openalex-extracted
Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1016/j.jtho.2019.10.004openalex-extracted
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
inferredcites →https://doi.org/10.1016/s0140-6736(13)62422-8openalex-extracted
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
inferredcites →https://doi.org/10.1016/s0140-6736(21)01234-4openalex-extracted
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045(15)00007-8openalex-extracted
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
inferredcites →https://doi.org/10.1016/s1470-2045(15)00040-6openalex-extracted
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(23)00541-7openalex-extracted
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
inferredcites →https://doi.org/10.1038/s41392-023-01576-4openalex-extracted
Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
inferredcites →https://doi.org/10.1056/nejmoa2112651openalex-extracted
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa2202170openalex-extracted
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
inferredcites →https://doi.org/10.1093/aje/kwac014openalex-extracted
On Variance of the Treatment Effect in the Treated When Estimated by Inverse Probability Weighting
inferredcites →https://doi.org/10.1093/annonc/mdy226openalex-extracted
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
inferredcites →https://doi.org/10.1097/01.pas.0000213312.36306.ccopenalex-extracted
Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome
inferredcites →https://doi.org/10.1097/js9.0000000000000978openalex-extracted
Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)
inferredcites →https://doi.org/10.1111/nyas.14508openalex-extracted
Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1136/jitc-2022-005830openalex-extracted
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
inferredcites →https://doi.org/10.1200/jco.20.03614openalex-extracted
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
inferredcites →https://doi.org/10.1245/s10434-011-2049-9openalex-extracted
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
inferredcites →https://doi.org/10.21037/atm-22-513openalex-extracted
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial…
inferredcites →https://doi.org/10.21037/jtd-23-84openalex-extracted
Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
inferredcites →https://doi.org/10.2147/jir.s424454openalex-extracted
Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
inferredcites →https://doi.org/10.3389/fimmu.2022.836338openalex-extracted
Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.